We noted a week ago Saturday, and analyzed on Thursday, the lawsuit that Allergan recently filed challenging the FDA’s regulations that forbid drug manufacturers from providing truthful information about off-label uses of drugs.

We also mentioned that we were disappointed to learn about the Allergan case by reading about it in The New York Times, rather than learning about it from our usual source — our readers, who typically report to (more…)